Abstract
AbstractTick‐borne encephalitis (TBE) is a natural focal disease with fatal encephalitis induced by tick‐borne encephalitis virus (TBEV), seriously threatening human and public health. Protection of TBE depends on vaccination with inactivated vaccine, which requires high cost and multiple immunizations. Here, we construct genetically engineered bacterial‐like particles (BLPs) as an effective TBEV vaccine with simplified immunizations and improved immune efficacy. The TBEV BLPs involve the combination of the gram‐positive enhancer matrix from Lactococcus lactis, and TBEV envelope (E) protein expressed by genetically engineered recombinant baculovirus. The prepared TBEV BLPs can effectively stimulate the activation of dendritic cells to present the TBEV E proteins to T and B cells, leading to strong and durable cellular and humoral immune responses in mice. Surprisingly, the serum levels of specific IgG antibodies in mice remain about 106 at 6 months after the secondary immunization. Overall, the TBEV BLPs can be used as a potent vaccine candidate, laying the foundation for developing novel TBEV genetically engineered vaccines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
